Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravesical Gemcitabine in Intermediate Risk Superficial Bladder Cancer
NCT00491114Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine in bladder cancer, sponsored by Eli Lilly and Company. Started Jul 2003; status: completed.
02
Drugs
gemcitabine
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT00491114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00491114.